View of Osimertinib as a third-generation EGFR TKI in non-small cell lung cancer: selective targeting of T790M mutation and clinical advantages

##article.return## Osimertinib as a third-generation EGFR TKI in non-small cell lung cancer: selective targeting of T790M mutation and clinical advantages Download Download PDF